Health & Research Goals
Fat Loss Duo
Dúo de Oxidación de Grasa
GLP-1 + Mitochondrial Metabolic Stack
Select a vial or the total
Primary Description
Semaglutide (GLP-1 agonist) regulates appetite signaling centrally. MOTS-C activates AMPK and mitochondrial energy metabolism. Two distinct, complementary pathways: one reduces caloric intake, the other optimizes fat oxidation.
Demonstrated Effects
- Sustained fat loss without metabolic slowdown
- Appetite suppression via GLP-1 receptor agonism
- MOTS-C prevents weight loss plateau
- Improved mitochondrial efficiency and energy
- Preserved lean mass during caloric deficit
Proposed Mechanisms of Action
Combined Mechanism
Semaglutide binds GLP-1 receptors in the hypothalamus, gut, and pancreas: reducing hunger signaling, slowing gastric emptying, and enhancing glucose-dependent insulin secretion. MOTS-C (a mitochondria-derived peptide) translocates to the nucleus and activates AMPK via the one-carbon folate cycle, upregulating fatty acid oxidation genes and preventing the metabolic adaptation (thyroid downregulation, leptin resistance) that typically causes weight loss plateaus.
Stack Compounds
Research Evidence & Clinical Data
Research Profile
Dual-mechanism metabolic optimizer targeting both hormonal appetite regulation and cellular energy metabolism. Semaglutide drives appetite suppression and weight loss via GLP-1 receptor agonism; MOTS-C activates intracellular exercise pathways that prevent the metabolic slowdown that typically accompanies caloric restriction — preserving fat loss momentum throughout the protocol.
Safety Profile
Common Side Effects
- Nausea, diarrhea, constipation common with GLP-1 initiation — titrate dose slowly
- Monitor blood glucose if taking antidiabetic medications
- Thyroid C-cell tumor class warning — monitor thyroid function
- Injection site reactions — rotate sites with each injection
- Pancreatitis risk — discontinue if severe abdominal pain
Contraindications
- Personal or family history of medullary thyroid carcinoma
- MEN2 (Multiple Endocrine Neoplasia type 2)
- Active pancreatitis
- Pregnancy or breastfeeding
Analytical Quality Assurance
Research Protocols
Dosing Protocols
Combined Research Protocol: Dúo de Oxidación de Grasa
Sub-QMonitoring & Risk Management
Compound Stack Monitoring
For stacks and blends, refer to the individual compound monographs for each included ingredient for specific monitoring guidelines.